

21.	Segment and Geographical Data

Through December 29, 2017, the Company operated its business under two reportable segments, which are described below:


•	Specialty Brands includes branded medicines; and


•	Specialty Generics includes specialty generic drugs, API and external manufacturing.

Management measures and evaluates the Company's operating segments based on segment net sales and operating income. Management excludes corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include, but are not limited to, revenues and expenses associated with sales of products to the acquirer of the CMDS business under an ongoing supply agreement, intangible asset amortization, net restructuring and related charges, non-restructuring impairments and separation costs. Although these amounts are excluded from segment operating income, as applicable, they are included in reported consolidated operating income and in the following reconciliations presented below.

Management manages assets on a total company basis, not by operating segment. The chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, the Company does not report asset information by operating segment. Total assets were approximately $15.3 billion and $15.2 billion at December 29, 2017 and December 30, 2016, respectively.

As a result of the sales of the CMDS and Nuclear Imaging businesses to Guerbet and IBAM, respectively, the financial results of these businesses are presented as discontinued operations. Therefore, prior year amounts have been recast to conform to current presentation.

Selected information by business segment is as follows:



	Fiscal Year Ended									Three Months Ended
	December 29, 2017			September 30, 2016			September 25, 2015			December 30, 2016
Net sales:
Specialty Brands	$	2,325.3		$	2,300.6		$	1,622.8		$	603.1
Specialty Generics	839.5			1,025.2			1,251.6			212.9
Net sales of operating segments ⁽¹⁾	3,164.8			3,325.8			2,874.4			816.0
Other ⁽²⁾	56.8			55.0			48.7			13.9
Net sales	$	3,221.6		$	3,380.8		$	2,923.1		$	829.9
Operating income:
Specialty Brands	$	1,155.2		$	1,166.2		$	637.6		$	317.2
Specialty Generics	231.5			376.1			594.4			52.7
Segment operating income	1,386.7			1,542.3			1,232.0			369.9
Unallocated amounts:
Corporate and allocated expenses ⁽³⁾	(172.0		)	(169.8		)	(282.6		)	(181.4		)
Intangible asset amortization	(694.5		)	(700.1		)	(550.3		)	(175.7		)
Restructuring and related charges, net ⁽⁴⁾	(36.4		)	(38.2		)	(45.3		)	(5.3		)
Non-restructuring impairments	(63.7		)	(16.9		)	—			(214.3		)
Operating income	$	420.1		$	617.3		$	353.8		$	(206.8	)

Depreciation and amortization ⁽⁵⁾:
Specialty Brands	$	708.2		$	716.6		$	559.5		$	178.4
Specialty Generics	100.1			96.8			81.6			24.8
	$	808.3		$	813.4		$	641.1		$	203.2


(1)	Amounts represent sales to external customers. There were no intersegment sales.


(2)	Represents net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.


(3)	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.


(4)	Includes restructuring-related accelerated depreciation.


(5)	Depreciation for certain shared facilities is allocated based on occupancy percentage.

Net sales by product family within the Company's segments are as follows:



	Fiscal Year Ended						Three Months Ended
	December 29, 2017		September 30, 2016		September 25, 2015		December 30, 2016
H.P. Acthar Gel	$	1,195.1	$	1,160.4	$	1,037.3	$	325.4
Inomax	505.2		474.3		185.2		118.3
Ofirmev	302.5		284.3		263.0		72.5
Therakos	214.9		207.6		—		47.4
Hemostasis products	55.1		42.5		—		13.4
Other	52.5		131.5		137.3		26.1
Specialty Brands	2,325.3		2,300.6		1,622.8		603.1

Hydrocodone (API) and hydrocodone-containing tablets	85.3		146.5		167.2		23.2
Oxycodone (API) and oxycodone-containing tablets	78.8		126.2		154.6		24.3
Methylphenidate ER	71.7		103.5		136.5		22.0
Other controlled substances	409.6		468.1		572.2		104.9
Other	194.1		180.9		221.1		38.5
Specialty Generics	839.5		1,025.2		1,251.6		212.9

Other ⁽¹⁾	56.8		55.0		48.7		13.9
Net sales	$	3,221.6	$	3,380.8	$	2,923.1	$	829.9


(1)	Represents net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.

Selected information by geographic area excluding assets held for sale is as follows:



	Fiscal Year Ended						Three Months Ended
	December 29, 2017		September 30, 2016		September 25, 2015		December 30, 2016
Net sales ⁽¹⁾:
U.S.	$	2,899.0	$	3,095.4	$	2,647.0	$	763.7
Europe, Middle East and Africa	242.3		211.8		159.0		52.8
Other	80.3		73.6		117.1		13.4
	$	3,221.6	$	3,380.8	$	2,923.1	$	829.9

	Fiscal Year Ended
Long-lived assets ⁽²⁾:	December 29, 2017		December 30, 2016
U.S.	$	788.5	$	759.1
Europe, Middle East and Africa ⁽³⁾	127.0		82.9
Other	63.5		51.5
	$	979.0	$	893.5


(1)	Net sales are attributed to regions based on the location of the entity that records the transaction, none of which relate to the country of Ireland.


(2)	Long-lived assets are primarily composed of property, plant and equipment, net.


(3)	Includes long-lived assets located in Ireland of $126.0 million and $80.9 million as of December 29, 2017 and December 30, 2016, respectively.